Flosonics Medical Secures Strategic Investment from Denka

09 Jul 2026

View Full Article

Latest

Flosonics Medical Secures Strategic Investment from Denka

Enspire DBS Therapy Announces $10.3 Million Series B1 Financing to Advance Pivotal Development of DBS-Enabled Stroke Rehabilitation

13 January 2026

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

11 December 2025

All Articles

Flosonics Medical Secures Strategic Investment from Denka

U of T, McMaster Announce Early-Stage Life Sciences Venture Fund With Genesys Capital

January 13, 2026

Enspire DBS Therapy Announces $10.3 Million Series B1 Financing to Advance Pivotal Development of DBS-Enabled Stroke Rehabilitation

December 11, 2025

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)